DataMeds AI Q3: $10.5M Net Income on Debt-Extinguishment Gain, Going Concern Persists
MEDS sits 31% above its 52-week low of $0.553.
Summary
DataMeds AI reported $10.5M of Q3 net income, almost entirely a non-cash gain on extinguishing the Wellgistics seller note, while operations still lost $3.4M and going-concern doubt remains with $23.7M of debt due within a year.
Key Events · Earnings and Guidance · MEDS
-
Q3 Profit Is a Non-Cash Debt Gain
Net income of $10,535,560 included a $19,064,881 non-cash gain on extinguishment of debt from the Wellgistics seller settlement; the loss from operations was $3,373,956.
-
Going Concern and Thin Liquidity
Cash was $476,598 with a working capital deficit of $31,329,749 and $23,722,342 of the $25,186,014 total debt principal due within twelve months; management cites substantial doubt about continuing as a going concern.
-
Revenue Mix Shifted to Pharmacy
Nine-month revenue fell 72.3% to $6,008,403 as distribution revenue collapsed to $330,120 from $20,854,677, offset by pharmacy retail sales of $5,117,974; Q3 gross margin rose to 16.2% from 7.7%.
-
Heavy Overhang From Convertibles and Warrants
Potentially dilutive securities total 17,387,018 shares versus 4,730,148 shares outstanding, including 9,442,355 warrants and 5,537,802 May 2026 note shares, with up to 20,323,732 shares issuable at the $1.00 floor.
Analysis · MEDS · Trade & Services
The headline profit is accounting, not operations. A $19.1M non-cash gain from extinguishing the $17.5M Wellgistics seller note and $1.7M of accrued interest produced $10.5M of Q3 net income, while the underlying business still lost $3.4M from operations. Cash is down to $476,598 against $23.7M of debt due within twelve months, and management repeats that substantial doubt exists about continuing as a going concern. Real structural change did arrive in the quarter: Helomics and the KareHub platform were folded in, the Wellgistics litigation was settled, and Nasdaq equity compliance was regained on October 19. Yet the REBOOT license and the terminated Second A&R LOI show the larger partner transaction fell apart. Existing holders face heavy future dilution: 17.4M potentially dilutive shares are outstanding against 4.7M shares outstanding, and the May 2026 notes alone could issue up to 20.3M shares at the $1.00 floor.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 49.5% of the 210 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MEDS was trading at $0.73 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $3.3M. The 52-week trading range was $0.55 to $35.50. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.